Scambia G, Ferrandina G, Marone M, Benedetti Panici P, Giannitelli C, Piantelli M, Leone A, Mancuso S
Department of Obstetrics and Gynecology, Catholic University, Rome, Italy.
J Clin Oncol. 1996 Feb;14(2):334-42. doi: 10.1200/JCO.1996.14.2.334.
The aim of the study was to define the prognostic role of the metastasis suppressor gene, nm23, in 106 primary ovarian cancer patients.
Northern and Western blotting analysis of nm23-H1 and nm23-H2 expression were performed in a subset of ovarian tumors. Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded specimens from 106 primary ovarian carcinomas by the antihuman nm23 monoclonal antibody.
Northern and Western blotting analysis demonstrated a direct association between nm23-H1 and nm23-H2 levels. Moreover, an overall concordance of 86.7% between Northern blotting and immunohistochemical data was observed. Sixty-six specimens (68%) showed a positive nm23-H1 immunoreaction. The percentage of nm23-H1 positivity was higher in lymph node-negative (70%) than in lymph node-positive cases (44%) (P = .049). Moreover, the percentage of complete/partial responses to chemotherapy was higher in nm23-H1-positive (69%) than in nm23-H1-negative (44%) patients (P = .03). The percentage of epidermal growth factor receptor (EGFR) positive cases was lower in nm23-H1-positive (44%) than in nm23-H1-negative immunostained (72%) samples (P = .012). Lower ras/p21 levels (median, 1.77 absorbance units) were found in nm23-H1-positive than in nm23-H1-negative samples (median, 2.63 absorbance units) (P = .03). The 6-year progression-free survival (PFS) rate of nm23-H1-positive cases was 50% (95% confidence interval [CI], 33 to 67) versus 12% (95% CI, -2 to 26) for nm23-H1-negative patients (P = .0056). In multivariate analysis, only stage, ascites, and nm23-H1 content retained independent prognostic roles.
The assessment of nm23 content may provide useful information for prognostic characterization of ovarian cancer patients.
本研究旨在明确转移抑制基因nm23在106例原发性卵巢癌患者中的预后作用。
对部分卵巢肿瘤进行nm23-H1和nm23-H2表达的Northern印迹和Western印迹分析。采用抗人nm23单克隆抗体，对106例原发性卵巢癌的福尔马林固定石蜡包埋标本进行免疫组织化学分析。
Northern印迹和Western印迹分析显示nm23-H1和nm23-H2水平之间存在直接关联。此外，观察到Northern印迹与免疫组织化学数据的总体一致性为86.7%。66例标本（68%）显示nm23-H1免疫反应阳性。nm23-H1阳性率在淋巴结阴性病例中（70%）高于淋巴结阳性病例（44%）（P = 0.049）。此外，nm23-H1阳性患者（69%）对化疗的完全/部分缓解率高于nm23-H1阴性患者（44%）（P = 0.03）。nm23-H1阳性样本（44%）中表皮生长因子受体（EGFR）阳性病例的百分比低于nm23-H1阴性免疫染色样本（72%）（P = 0.012）。nm23-H1阳性样本中ras/p21水平（中位数，1.77吸光度单位）低于nm23-H1阴性样本（中位数，2.63吸光度单位）（P = 0.03）。nm23-H1阳性病例的6年无进展生存率（PFS）为50%（95%置信区间[CI]，33至67），而nm23-H1阴性患者为12%（95%CI，-2至26）（P = 0.0056）。在多变量分析中，只有分期、腹水和nm23-H1含量保留独立的预后作用。
nm23含量的评估可为卵巢癌患者的预后特征提供有用信息。
